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A B S T R A C T
Redox signaling has been established as an essential component of inflammatory responses, and redox active compounds are of interest as potential im-
munomodulatory agents. Dibenzocyclooctadiene lignans isolated from Schisandra chinensis, a medicinal plant with widespread use in oriental medicine, have been
implicated to possess immunomodulatory properties but their effects on the human innate immune system cells have not been described. In this contribution, data are
presented on the impact of schisandrin, schisandrin B and schisandrin C on human monocytic cell redox status, as well as their impact on dendritic cell maturation
and T cell activation capacity and cytokine production. In THP-1 cells, levels of intracellular reactive oxygen species (ROS) were elevated after 1 h exposure to
schisandrin. Schisandrin B and schisandrin C decreased cellular glutathione pools, which is a phenotype previously reported to promote anti-inflammatory functions.
Treatment of human primary monocytes with the lignans during their maturation to dendritic cells did not have any effect on the appearance of surface markers HLA-
DR and CD86 but schisandrin B and schisandrin C suppressed the secretion of cytokines interleukin (IL)-6, IL-10 and IL-12 by the mature dendritic cells. Dendritic
cells maturated in presence of schisandrin C were further cocultured with naïve CD4+T cells, resulting in reduced IL-12 production. In THP-1 cells, schisandrin B
and schisandrin C reduced the IL-6 and IL-12 production triggered by E. coli lipopolysaccharide and IL-12 production induced by an infection with Chlamydia
pneumoniae. In conclusion, the studied lignans act as immunomodulatory agents by altering the cytokine secretion, but do not interfere with dendritic cell ma-
turation. And the observed effects may be associated with the ability of the lignans to alter cellular redox status.
1. Introduction
Schisandra chinensis represents one of the oldest medicinal plants
used in traditional Chinese and other East-Asian medicine [1]. During
the past few decades, the berry extract of this herb has become more
popular also in the western world. Traditionally the berry extracts of S.
chinensis are considered as tonic and liver protective agents and they are
currently often referred as adaptogens [1–3]. Dibenzocyclooctadiene
lignans are the dominant secondary metabolite components in the
berries and various biological activities have been associated with these
compounds [3,4]. Schisandrin and schisandrin B are the most abundant
lignan constituents in the berries and, therefore, the most studied ones
as well.
The biological and pharmacological activities associated with the S.
chinensis lignans include neuro-, cardio- and hepatoprotective effects, as
well as anti-cancer activities [5–8]. As illustrative examples, Lee and
colleagues demonstrated that schisandrin B inhibits cortical neuronal
damage in a rat stroke model [6]. Schisandrin B has also been reported
to protect murine brain against beta amyloid toxicity [9] and to protect
liver against chemically induced toxicity [8,10,11]. Regarding anti-
cancer properties, schisandrin B has been shown to inhibit the lung and
bone metastases in BALB/c mice inoculated with breast cancer 4T1
cells, by inhibiting the epithelial-mesenchymal transition (EMT) [7].
Another S. chinensis metabolite, schisandrin C, induces cell cycle arrest
and apoptosis in human leukemia U937 cells [12]. Furthermore, schi-
sandrin lignans may reverse P-glycoprotein mediated drug resistance of
several multidrug resistant cell lines [13].
To date, the anti-inflammatory properties of the S. chinensis lignans
have mostly been studied in murine cell lines and animal models sti-
mulated by bacterial lipopolysaccharides (LPS) [14–17]. In these
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studies, the impact of different lignans on reactive nitrogen species
(RNS) and reactive oxygen species (ROS) have been addressed. ROS and
RNS are essential mediators and messenger molecules of immune
system and gene expression [18,19]. Owing to its direct antimicrobial
actions and ability to induce cytokine production, nitric oxide (NO)
plays an important role in immunity [17,20]. Despite the physiological
role of NO, other RNS and ROS in inflammatory responses, their
overproduction may result in tissue injury [18]. S. chinensis berry ex-
tract has been shown to inhibit LPS-induced NO production and sup-
press NO synthetase levels in murine macrophages [20]. Schisandrin,
schisandrin B and other lignin constituents of the extract have been
reported with similar effects both in vitro and in vivo [14,17]. How-
ever, while NO production is a prominent and well-established property
of monocytic and macrophage cell of rodent origin, NO production by
human monocytic cells has been a matter of debate [21–25].
Another previously studied aspect of immunomodulatory effects
exhibited by schisandrin lignans is their impact on cytokine secretion
[16,17]. Cytokines are small protein molecules that have various
functions which regulate the immune reactions of the cells [26]. They
are produced by various cell types as a response to endogenous or
exogenous stimuli and are able to activate and inhibit cell functions,
regulate cell differentiation and act chemotactically in case of tissue
injury [27]. In systemic level, the interplay of cytokines acting pro-in-
flammatory to destroy pathogens by inflammation and anti-in-
flammatory to prevent unnecessary tissue damage is essential to
maintain body homeostasis [28].
Previous studies have implicated that schisandrin B suppresses in-
terleukin (IL)-6 and IL-1β secretion in LPS-treated microglia [29] and
IL-2, IL-4 and IL-6 production in murine splenic lymphocytes [16].
Schisandrin B and schisandrin C have also been reported to diminish IL-
1β, IL-6 and tumor necrosis factor (TNF)-α production in LPS-stimu-
lated murine macrophage cell line, RAW264,7 [17]. All these studies
involve the use of rodent models, and only a few studies have been
carried out with human cell models. Lin et al. [30] reported that schi-
sandrin B inhibited the LPS-induced production of IL-8 and TNF-α in
human umbilical vein endothelial cells (HUVEC) and increased the
expression of transcription factor Nrf2 and blocked the activation of NF
-κB. In human monocytic THP-1 cells, suppression of acne-related in-
flammation by the lignans has recently been reported [31] but other-
wise, the impact of S. chinensis -derived compounds on human innate
immune system cells remain unstudied.
The antioxidant properties of schisandrin lignans have been sug-
gested to mediate their anti-inflammatory responses [14]. In mouse
splenic T lymphocytes, schisandrin B has been shown to increase the
production of ROS and alter the redox balance in the cells, leading to
increase in the redox sensitive transcription factor Nrf2 levels and de-
crease in activation of pro-inflammatory transcription factor NF -κB
[16]. Also, altering cellular glutathione (GSH) homeostasis has been
linked to its anti-inflammatory activities. Schisandrin B increased the
oxidation level of glutathione (GSH:GSSG ratio) in T lymphocytes [17].
The increase in hepatic GSH levels by schisandrin B has been suggested
to mediate its hepatoprotective effect [5] and increase in reduced GSH
levels in solar irradiated human fibroblasts has been reported after
schisandrin B and schisandrin C treatment [32].
In the present study we examined the effects of schisandin, schi-
sandrin B and schisandrin C (Fig. 1) on human innate immune system
cells. Two widely used and well established models were used: mono-
cyte derived dendritic cells (DCs) obtained from healthy donors and
THP-1 cell line [33,34]. The effect of the schisandrin, schisandrin B and
schisandrin C on monocytic glutathione pools was evaluated. Based on
these findings DC maturation was studied by evaluating their expres-
sion of surface marker proteins. In addition, the impact of schisandrin C
treated DCs on T cell activation was addressed. Cytokine secretion by
DCs, T-cells and monocytes was evaluated after stimulation with E. coli
LPS. As an alternative trigger for the inflammatory state the infection of
monocytes by Chlamydia pneumoniae was used to gain more
comprehensive picture of the anti-inflammatory properties of the lig-
nans.
2. Materials and methods
2.1. Compounds
Schisandrin was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Schisandrin B and schisandrin C were obtained from Fine Tech
Industries (London, UK). 20mM stock solutions of the lignans were
prepared in DMSO and diluted in cell culture media at final con-
centrations indicated for each experiment.
2.2. THP-1 culture
All cell cultures were maintained and incubated during the experi-
ments at 37 °C, 5% CO2 and 95% air humidity unless otherwise men-
tioned in the text.
Human monocyte cell line THP-1 (ATCC TIB202) was cultured in
RPMI 1640 (Dutch edition) medium (Gibco, Invitrogen, Thermo Fisher
Scientific, Paisley, UK) with 10% fetal bovine serum (FBS)
(BioWhittaker, Lonza, Basel, Switzerland), 2 nM L-glutamine
(BioWhittaker), 0.05mM 2-mercapthoethanol (Gibco) and 20 µg/ml
Gentamicin (Fluka, Buchs, Switzerland).
For cytokine secretion experiments THP-1 cells were seeded in 48-
well plate into density at 5× 105 cells/ml. In experiments stimulated
by LPS, 50 U/ml of interferon (IFN)-γ (R&D Systems) were added and
Fig. 1. Chemical structures of dibenzocyclooctadiene lignans a.) schisandrin,
b.) schisandrin B and c.) schisandrin C.
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cells were incubated for 3 h. Then, 0.75 µg/ml of E. coli LPS (Fluka,
Sigma) and schisandrin lignans in final concentration of 25 µM and
50 µM were added. As vehicle control, 0.25% DMSO was applied. In
experiments involving C. pneumoniae infection the bacterium inoculum
(strain K7, prepared as previously described [35]) was added into the
wells at multiplicity of infection (MOI) 2 and the plates were cen-
trifuged at 550× g for 1 h. After consequent 1 h incubation at 37 °C The
lignans and vehicle control were added as described above. With either
stimulus the cultures were incubated for 48 h and centrifuged at
1100 rpm for 10min. Supernatants were collected and stored at
−80 °C.
2.3. Culture of dendritic cells
DCs were obtained as previously described [36]. In short, peripheral
blood mononuclear cells (PBMCs) were obtained by density gradient
centrifugation of blood of healthy volunteers using Histopaque® 1077
(Sigma, Münich, Germany). Monocytes expressing CD14 were isolated
from peripheral blood mononuclear cells using beads-labeled anti-CD14
antibodies (CD14 MicroBeads) and magnetic cell sorting (MACS) (both
from Miltenyi Biotech, Bergisch Gladbach, Germany). The monocytes
were cultured at 5×105 cells/well in 48-well plates (Nunc, Roskilde,
Denmark) in RPMI 1640 medium (Gibco) with 10% FBS (Gibco) and
differentiated to immature DCs (imDCs) with GM-CSF (25 ng/well) and
IL-4 (12.5 ng/well) (both from R&D Systems). Fresh medium and cy-
tokines were added on day three. On day 7 the cells were harvested and
cultured at 1.25× 105 cells/well in RPMI 1640 medium with 10% FBS.
The cells were cultured in the presence of IL-1β (5 ng/well, TNF-α,
25 ng/well (both from R&D Systems) and LPS 250 ng/well (Sigma),
which turns the imDCs into mature DCs (mDCs). The schisandrin lig-
nans were added to the wells at 25 and 50 µM. Some wells were left
without compounds and served as negative control. For solvent control,
0.25% DMSO was included in some well as vehicle control. Cells were
incubated for 48 h. On day 9 the cells were harvested and the ma-
turation evaluated by measuring expression of surface molecules by
flow cytometry and secretion of cytokines by ELISA. In some experi-
ments the DCs were used in co-culture experiments.
2.4. Co-culture of mCDs and allogenic CD4+ T cells
In order to investigate the effect of DCs matured in the presence of
schisandrin lignans on the activation and differentiation of T cells,
mDCs were co-cultured with allogeneic CD4+T cells. The CD4+T
cells were obtained from the whole blood using the same method as
described for CD14 monocytes except using CD4 MicroBeads
(Miltenyi). The CD4+T cells were diluted to a final concentration of
2× 106 cells/ml. mDCs which had been maturated with 50 µM schi-
sandrin C or vehicle control only were collected on day 9 and re-
suspended at 2×105 cells/ml. The mDCs and T cells were cultured in
U-bottomed 96-well plates (Nunc) at 1:10 ratio (2×104 DCs/
well:2×105 T cells/well). The cells were cultured for six days. Then the
cells were harvested and the activation and differentiation of the T cells
evaluated by measuring expression of surface molecules by flow cyto-
metry and secretion of cytokines by ELISA.
2.5. Measurement of surface marker expression by flow cytometry
The purity of isolated CD4+ T cells and CD14+monocytes, the
differentiation of monocytes into imDCs, maturation of imDCs into
mDCs, the effect of schisandrin lignans on DC maturation and the effect
of schisandrin C-treated DCs on activation and differentiation of
CD4+T cells was analyzed by flow cytometry. The cells were stained
with fluorochrome labeled monoclonal antibodies and incubated on ice
for 20min. The cells were washed with staining buffer and resuspended
in 300 µl of 1% paraformaldehyde. Ten thousand cells for each staining
were collected with FACScaliber flow cytometer (BD Biosciences, San
Jose, CA) and analyzed with CellQuest Pro software (BD Biosciences).
The results were given as percentage positive cells or mean fluorescence
intensity (MFI). The antibodies used for staining of CD14+monocytes,
imDCs and mDCs were against CD86, HLA-DR and CD14 (all from BD
Biosciences). The antibodies for staining of CD4+T cells were against
CD4, CTLA4 and CD69 (all from BD Biosciences). Appropriate isotype
control antibodies were used to set gates.
2.6. Cell viability assay
The impact of studied lignans on THP-1 cell viability was evaluated
with resazurin cytotoxicity assay. The cells were seeded into 96-well
plates at density of 6×104 cells/well and the lignans were added at
25 μM and 50 μM. 200 μM usnic acid (Sigma) and 1% Triton X-100
(Sigma) were used as positive controls and 0.25% DMSO as a vehicle
control. After 4 h, 24 h and 48 h incubation, resazurin (Sigma, 3mM
stock dissolved in H2O) was added to yield a final concentration of
20 μM. The cultures were incubated for 2 h and fluorescence was re-
corded at 570/590 nm with Varioskan Lux plate reader.
2.7. Measurement of cytokines by ELISA
The effect of schisandrin lignans on cytokine secretion by mDCs, T
cells and THP-1 cells was measured by sandwich ELISA by using
DuoSets kits from R&D Systems, according to the manufacturer's in-
structions. IL-6, IL-10 and IL-12p40 levels were measured in super-
natants from THP-1 cells or mDCs and IL-6, IL-10. IL-12p40, IL-13 and
IFN-γ in co-culture supernatants. In brief, the 96-well plates were
coated overnight in room temperature with the capture antibody di-
luted in PBS. Next day the capture antibody was discarded, wells were
washed with wash buffer (0.05% Tween 20 in PBS) and blocking so-
lution (1% BSA in PBS for THP-1, 1% BSA, 5% sucrose and 0.05% NaN3
in PBS for DCs and T cells) was added. After 1 h incubation at RT the
wells were washed, samples and standards were added and incubated
for 2 h at RT. Then, plates were washed, detection antibody were added
and incubated 2 h at RT. Then the wells were washed and HRP –con-
jugated Streptavidin was added and incubated for 20min at RT. The
wells were washed again and the substrate solution were added and
incubated until the color developed in the highest standard. The stop
solution (2 N sulphuric acid) was applied and the optical density was
determined by Varioskan lux plate reader set to 450 nm. The con-
centration of cytokines in pg/ml were read from seven-point standard
curves. The results were given as secretion index (SI) which was cal-
culated by dividing the concentration of cytokine in supernatant from
cells treated with schisandra lignans by the concentration of cytokine in
supernatant from cells treated with vehicle control (DMSO).
2.8. Intracellular ROS detection
The intracellular ROS levels of THP-1 cells were studied with di-
chlorodihydrofluorescein diacetate (DCFH-DA) (Sigma-Aldrich). After
being washed with PBS, 1.5× 105 of THP-1 cells were incubated in
microcentrifuge tubes with 20 μM DCFH-DA for 30min. After incuba-
tion, DCFH-DA was removed, cells washed with PBS and lignan samples
(25 μM and 50 μM) and 0.25% DMSO vehicle control were added to the
tubes. After 1 h incubation cells suspensions were transferred to 96-well
plate for the fluorescent readout. The fluorescence was recorded at
503/523 nm with Varioskan lux plate reader (Thermo Fisher Scientific).
One mM hydrogen peroxide (Sigma-Aldrich) was used as a positive
control.
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2.9. Glutathione and glutathione disulfide quantification assay
The intracellular GSH and GSSG levels of THP-1 cells were studied
using method described previously by Rahman et al. [37]. In brief,
THP-1 cells were seeded into 24-well plates at density of 4×105 cells/
ml and incubated 4 h, 24 h or 48 h with schisandrin, schisandrin B and
schisandrin C at 25 μM and 50 μM. 0.25% DMSO was used as vehicle
control. Cells were lysed and stored at −70 °C. To measure total GSH,
83.3 units/ml of glutathione reductase (GR) were added to the sample
with 666 μg/ml of 5.5-dithio-bis(2-nitrobenzoic acid) (DTNB). After
30 s, 666 μg/ml of β-NADPH were added and the formation of TNB
chromophore product was recorded by Multiskan Sky plate reader at
412 nm. To detect the GSSG, 9.5% 2-vinylpyridine was added and after
1 h incubation 16.3% triethanolamine was applied. Then GR, DTNB and
β-NADPH were added and the amount TNB was recorded as described
above.
2.10. Nitrite quantification assay
For analysis of NO production in THP-1 cells were seeded into 24-
well plates at density of 4× 105 cells/ml. To differentiate cells to
macrophage-like phenotype, the cultures were treated with 160 nM
phorbol 12-myristate 13-acetate (PMA) for 48–72 h. Cells were then
treated with 1 µg/ml E. coli LPS (Fluka, Sigma) for 4 – 72 h. Luteolin
(10 μM) was used as positive control and 0.25% DMSO as vehicle
control. The total nitrate concentrations, indicative of NO, were quan-
tified using Griess Reagent which is a mixture of two solutions: N-1-
naphtylethylenediamine dihydrochloride (Sigma-Aldrich) and Milli-Q
H2O; 2% sulfanilamide (Sigma-Aldrich) and 5% phosphoric acid diluted
from 85% orto-phosphoric acid. Sample of 100 µl of each culture su-
pernatant were pipetted into wells on 96-well plates and 100 µl of
Griess reagent, freshly prepared, was added. Absorbance was de-
termined by Varioskan lux plate reader (Thermo Fisher Scientific) set to
540 nm.
2.11. Data analysis
The data were expressed as mean± standard error of mean (SEM).
Statistical analyses were performed using SPSS Statistics 24 software.
The statistical significance of results of THP-1 cytokine studies were
analyzed using one-way ANOVA with Games-Howell post hoc test.
Kruskall-Wallis test was used for studies on DCs and Student t-test with
Bonferroni correction for GSH and ROS assays. P values< 0.05 were
considered as statistically significant.
3. Results
3.1. Impact of schisandrin lignans on intracellular ROS and glutathione
levels
The study was initiated by examining the impact of the three schi-
sandrin lignans on human monocytic cell redox status. THP-1 cells were
incubated with schisandrin, schisandrin B and schisandrin C for 1 h and
intracellular ROS levels were determined. As shown in Fig. 2A, schi-
sandrin increased the intracellular ROS levels at both 25 μM (43%) and
50 μM (50%) concentrations. No differences in ROS levels compared to
the vehicle control were observed with schisandrin B or schisandin C.
Next, GSH and GSSG levels of THP-1 cells were determined after 4 h,
24 h and 48 h incubation with the schisandrin lignans. Shcisandrin B
lowered the total GSH concentrations by 35% (25 μM) and 50% (50 μM)
after 4 h incubation and schisandrin C (50 μM) lowered the levels by
38% (Fig. 2B). After 24 h incubation schisandrin B at 50 μM con-
centration lowered the total GSH levels by 48% and after 48 h schi-
sandrin B 25 μM and 50 μM, as well as schisandrin C 50 μM lowered the
GSH levels by 53%, 73% and 50%, respectively. In the conditions used,
GSSG concentrations remained below the detection limit of the assay
and thus are not reported. To rule out direct cytotoxic effects of the
lignans, resazurin cell viability assay on THP-1 cells was carried out
after 4 h, 24 h and 48 h exposure, respectively. In these assays, cell
viability was not affected in any of the lignin-treated samples (data not
shown).
3.2. NO production in THP-1 cells
Earlier reports on the immunomodulatory properties of S. chinensis
lignans have presented data on the impact of these compounds on
murine macrophage NO production [14]. In our studies, data essen-
tially similar to the previously published were obtained with RAW264.7
cells (supplementary Fig. S1). E. coli LPS induced significant NO pro-
duction in these cells, and the total nitrate levels quantified with the
Griess reagent were suppressed by the studied lignans schisandrin,
schisandrin B and schisandrin C. However, in contrary to previous
findings [15], altering the administration times did not significantly
affect the cellular responses in our study.
Despite the obvious activation of NO production in RAW264.7 cells
(suppl. Fig. 1), no elevation of nitrate levels was observed in the human
leukemia cell line THP-1, neither in its monocytic nor macrophage form
in any of the time points studied (from 4 h to 72 h; data not shown).
While some controversial data have been presented in the literature,
this finding was in line with earlier observations [38–40], and the im-
pact of the S. chinensis lignans on this aspect of human monocyte im-
mune responses was thus not addressed in this study
Fig. 2. Effects of schisandrin lignans on intracellular ROS and total GSH levels
in THP-1 cells. The cells were treated with 25 μM and 50 μM concentration of
schisandrin, schisandrin B and schisandrin C and basal intracellular ROS levels
were measured after 1 h incubation with DCFH-DA (A). Total intracellular GSH
concentration of THP-1 cells after 4 h, 24 h and 48 h incubation with 25 μM and
50 μM schisandrin, schisandrin B and schisandrin C (B). Data are normalized as
a ration of DMSO control and shown as mean± SEM and statistical sig-
nificance is presented as marks of P values:< 0.05: * ;< 0.01: * *;< 0.001:
* ** . n≥ 4.
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3.3. The effect of schisandrin lignans on surface marker expression on DCs
We then evaluated the impact of the three studied lignans on the
maturation process of dendritic cells, applying CD14+monocytes iso-
lated from healthy human volunteers. Differentiation of
CD14+monocytes into imDCs and subsequent maturation into mDCs
was confirmed by staining the cells with antibodies against CD86 and
HLA-DR, which are expressed in low levels on monocytes and imDCs
but at high levels on mDCs. As expected, mature dendritic cells had
significantly higher levels of CD86 and HLA-DR expression as compared
with imDCs and monocytes (p < 0.05), indicating that maturation had
occurred by the treatment with maturation factors (Fig. 3). Maturing
the DCs in the presence of schisandrin, schisandrin B or schisandrin C
had no effect on the expression of CD86 and HLA-DR as compared with
vehicle-treated DCs, indicating that the schisandrin lignans did not af-
fect the maturation of the DCs.
3.4. Impact on cytokine secretion by mature dendritic cells
After confirming that the schisandrin lignans did not affect the
maturation of the DCs their effect on cytokine secretion was evaluated.
All three lignans showed some tendency towards downregulation of IL-
6, IL-10 and IL-12p40 secretion by the mDCs as compared with vehicle-
treated DCs. DCs matured in the presence of schisandrin B and schi-
sandrin C at 25 and 50 µM secreted lower levels of IL-6 as compared
with DCs treated with vehicle (concentration 30260 pg/ml) (Fig. 4A).
DCs treated with 25 µM schisandrin B secreted lower levels of IL-10
than DCs treated with vehicle (5800 pg/ml) (Fig. 4B). DCs matured in
the presence of schisandrin at 25 and 50 µM and schisandrin C at 25 and
50 µM secreted lower levels of IL-12p40 compared with DCs treated
with vehicle (18368 pg/ml) (Fig. 4C).
3.5. Impact of schisandrin C on cytokine secretion of the co-cultured DCs
and T cells
In order to investigate the subsequent differentiation of naïve
CD4+T cells when co-cultured in the presence of mDCs, their levels of
IL-6, IL-10, IL-12p40, IL-13, and IFN-γ secretion was measured. The DCs
in the co-culture were matured in the presence of 50 µM schisandrin C.
Based on data presented above, schisandrin C was chosen to this ana-
lysis. The concentrations of IL-6, IL-10, IL-12p40, IL-13 and IFN-γ were
all elevated implying that T cells had become activated by mDCs and
produced cytokines. The co-culture of T cells and the mature DCs
Fig. 3. Effect of the schisandrin lignans on the expression of CD86 and HLA-DR.
Monocytes (MCs) were differentiated into immature dendritic cells (imDCs) and
then maturated with IL-1β, TNF-α and LPS into mature dendritic cells (mDCs)
with nothing added (Neg), vehicle only (DMSO) or in the presence of schi-
sandrin, schisandrin B and schisandrin C at 25 and 50 µM. The expression of
HLA-DR (A) and CD86 (B) was measured by flow cytometry and the results give
as mean fluorescence intensity (MFI). Data are presented as mean MFI± SEM,
n= 8.
Fig. 4. IL-6, IL-10 and IL-12p40 levels. DCs were matured with IL-1β, TNF-α
and LPS in the presence of presence of schisandrin, schisandrin B and schi-
sandrin C at 25 and 50 µM or vehicle only and their secretion of IL-6 (A), IL-10
(B) and IL-12p40 (C) was measured with ELISA. The results are given as se-
cretion index (SI) which is calculated by dividing the concentration of cytokine
in supernatant of DCs maturated in the presence of schisandrin lignans by the
concentration of cytokines in supernatant of DC treated with vehicle. Data are
presented as mean SI± SEM, n= 8. Statistical significance is presented as
marks of P values:< 0.05: * ;< 0.01: * *;< 0.001: * ** . Full datasets of de-
tected cytokine concentrations are available in Mendeley data repository as a
MS Excel file linked to this article.
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treated with schisandrin C secreted significantly lower levels of IL-12
(SI 0,62) compared with cocultures with untreated DCs (Table 1).
Schisandrin C also seemed to decrease the levels of IL-6 (SeI 0.90,
p=0.17), IL-10 (SeI 0.86, p= 0.68) and IFN-γ (SeI 0.78, p=0.36))
compared to vehicle control. The level of IL-13 (SeI 1.89, p=0.20)
seemed to be increased in presence of schisandrin C.
The impact of schisandrin C-treated DCs on T cell activation and
differentiation was also evaluated by measuring the T cell surface
proteins CTLA-4 and CD69. However, no differences in the expression
of these two T cell activation markers were observed between T cells co-
cultured with schisandrin C-treated DCs or vehicle-treated DCs (data
not shown).
3.6. Impact of schisandrin lignans on IL-6 and IL-12 production in THP-1
cells
For comparison, the human monocytic cell line THP-1 was also
applied for analyzing the ability of schisandrin lignans to suppress cy-
tokine production. THP-1 cells were stimulated with LPS from E. coli
and IFN-γ and then treated with schisandrin, schisandrin B and schi-
sandrin C to evaluate the impact of the lignans on their cytokine se-
cretion. All three schisandrin lignans seemed to lower the concentra-
tions of LPS induced IL-6 levels compared with DMSO control (2778 pg/
ml or 2152 pg/ml) (Fig. 5A). Both concentrations of schisandrin B and
achisandrin C lowered the IL-6 levels statistically significantly. All three
compounds also seemed to reduce the IL-12p40 concentrations com-
pared to DMSO control (644 pg/ml or 1327 pg/ml) (Fig. 5B). At both,
25 μM and 50 μM, concentrations, the IL-12p40 reduction was statisti-
cally significant with schisandrin B. Schisandrin C lowered the IL-12p40
levels statistically significantly at 50 μM concentration. Schisandrin also
seem to lower the IL-12p40 levels but the reduction was not statistically
significant. IL-10 production of THP-1 cells was also studied, but the
production was not activated significantly when treated with IFN-γ and
LPS. Highest IL-10 concentrations determined were only 10 pg/ml in
these conditions.
Besides the activation by E. coli LPS and IFN-γ, THP-1 cells were also
stimulated to produce cytokines by an infection with the obligate in-
tracellular bacterium Chlamydia pneumoniae and treated with schisan-
drin, schisandrin B and schisandrin C. Schisandrin B and schisandrin C
decreased the IL-12p40 levels in statistically significant manner, com-
pared to DMSO control (47 pg/ml at most) (Fig. 5C). The IL-12p40
concentrations of untreated samples of cells induced by LPS were much
higher than C. pneumoniae induced cells indicating the differences in
the antigenic properties of LPS of E. coli and C. pneumoniae. THP-1 cells
did not produce significant amount of IL-6 when induced with C.
pneumoniae infection.
4. Discussion
The dibenzocyclooctadiene lignans isolated from Schisandra chi-
nensis have been widely studied for their biological activities, involving
among others, anti-inflammatory and immunomodulatory properties.
The current work contributes to the knowledge on these commonly
consumed compounds regarding their impact on the redox status and
activation of the cells of human innate immune system. Despite the
widespread use of S. chinensis extract, no data on human plasma or
target tissue concentrations of individual lignans after their oral ad-
ministration are available. In recently published pharmacokinetic stu-
dies of schisandrin and schisandrin B in rats, micromolar plasma peak
concentrations of both lignans have been reported after single dose oral
administration [41,42]. Even though the influence of multiple dosing,
tissue distribution and inter-species variation in the kinetics of the
lignans remain unknown, the concentrations used in this study can be
considered achievable in vivo.
Table 1
Effect of schisandrin C-treated DCs on T cells. DCs matured in the presence of
50 µM schisandrin C (DC-Sch C) or vehicle only (DC-DMSO) were co-cultured
with allogeneic CD4+T cells. The secretion of IL-6, IL-10, IL12p40, IL-13 and
IFN-γ in the culture supernatant was measured by ELISA. The results are given
as secretion index which is calculated by dividing the concentration of cytokine
in supernatant of co-culture of DC-Sch C and T cells by the concentration of
cytokines in supernatant of co-culture of DC-DMSO and T cells. Data are pre-
sented as mean SI± SEM, n=6. Statistical significance is presented as marks
of P values:< 0.05: * ;< 0.01: * *;< 0.001: * ** . Full datasets of detected
cytokine concentrations are available in Mendeley data repository as a MS Excel
file linked to this article.
Cytokine Secretion index (DC-Sch C+T/DC-DMSO+T)
IL-6 0.899 ± 0.069
IL-10 0.861 ± 0.327
IL-12p40 0.617 ± 0.069***
IL-13 1.888 ± 0.365
INF-γ 0.778 ± 0.232
Fig. 5. Cytokine production of THP-1 cells. LPS induced IL-6 (A) and IL-12p40
(B) concentrations and C. pneumoniae induced IL-12p40 (C) concentrations in
THP-1 cell samples in presence of INF-γ (LPS induced samples) and Scisandrin
lignans. THP-1 cells were treated with 25 μM and 50 μM concentration of
schisandrin, schisandrin B and schisandrin C. Data is presented as secretion
index (SeI) as mean± SEM and statistical significance is presented as marks of
P values:< 0.05: * ;< 0.01:* *;< 0.001:* ** . n≥4. Full datasets of detected
cytokine concentrations are available in Mendeley data repository as a MS Excel
file linked to this article.
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GSH is an essential endogenous antioxidant agent present both in-
side cells and in extracellular space [43]. It protects cells from oxidative
damage via eliminating radicals by the virtue of GSSG formation, and
depletion of cellular glutathione pools may occur as a response to
chemical toxicant exposure. Previously, it has been reported that schi-
sandrin B elevates the chemically depleted GSH levels in different cells
and tissues [5,32,44,45]. In the current contribution, we studied the
effects of schisandrin lignans on basal GSH levels in THP-1 cells, a
human monocytic cell line. According to our data (Fig. 2B), schisandrin
B and schisandrin C but not schisandrin, cause a drastic decrease in
cellular GSH pools already after 4 h incubation, and similar effect is
seen after 48 h exposure. While Checker et al. have reported a decrease
in GSH:GSSG ratio after a 4 h treatment of murine splenic lymphocytes
with schisandrin B [16], no earlier reports on decrease in total cellular
glutathione content upon schisandrin B or schisandrin C are available.
Owing to homeostatic mechanisms, decrease of intracellular glu-
tathione pools may also have beneficial effects on cellular physiology
[46]. Several studies have reported the suppression of NF-κB mediated
transcriptional activity by chemical agents which induce cellular GSH
depletion [47–49]. The suggested mechanisms underlying this phe-
nomenon involves the oxidation of a cysteine residue in the DNA-
binding domain of NF-κB, resulting in weakened ability of the activated
transcription factor to bind DNA. Furthermore, the Nrf2 transcription
factor is activated by oxidative stress [50] which downregulates NF-κB,
shifting the cell towards an anti-inflammatory phenotype [47]. Both
suppression of NF-κB activity and activation of Nrf2 have been reported
to occur as a result of schisandrin B and C treatment [16,17,30], and
even though not a subject of experiments in the current work, this can
be speculated to result from altered GSH levels.
In earlier studies on schisandrin lignans, it has been suggested that
the oxidative metabolism of these lignans results in the increase in in-
tracellular ROS levels which may mediate the protective effects
[16,32,51–53]. It seems, however, that such events are dependent on
cell type and additional stimuli, as other studies have linked schisandrin
lignan treatment with either no changes in ROS production [54,55] or
suppression of ROS production after various stimuli [9,56–61] In
human monocytic THP-1 cells, only schisandrin elevated ROS levels
while schisandrin B and schisandrin C did not affect the ROS levels after
1 h (Fig. 2A). Based on our data, the possible ROS elevation by schi-
sandrin B and schisandrin C after longer exposure cannot be ruled out
but it seems obvious that the ability of the lignans to decrease cellular
GSH pools is not associated with a rapid increase in cytosolic ROS. A
similar phenotype involving GSH depletion with no cytosolic ROS ele-
vation has recently been linked to mitochondrial oxidative stress [34].
Furthermore, the impact of schisandrin B and schisandrin C on GSH
levels was less obvious at 24 h than at 4 h or 48 h, implying that a more
detailed study with more specific probes on the kinetics of cellular
redox status after exposure to different lignans would be necessary to
elucidate the underlying molecular events. It can be speculated, how-
ever, that the immediate ROS production by schisandrin may contribute
to the GSH level maintenance through homeostatic mechanisms and
result in ineffective anti-inflammatory response in THP-1 cells. In
contrast, decrease in cellular GSH upon schisandrin B and schisandrin C
exposure can be hypothesized to mediate the anti-inflammatory effects
discussed below.
DCs are a diverse population of immune cells with an essential role
in induction and regulation of immune responses [62]. Specialized in
antigen capture, processing and presenting this small fraction of he-
matopoietic cells is responsible for priming naïve T cells and thereby
govern the immunogenic and tolerogenic features of the adaptive im-
mune system [63]. Originating from bone marrow, the DC precursors
migrate to the blood stream and non-lymphoid tissues where they de-
velop to imDCs under the influence of various growth factors. Pheno-
typic and functional maturation to mDCs occurs upon recognition of
foreign matter by toll-like receptors (TLRs) [64]. Interference of DC
maturation may involve functions like antigen-processing capacity,
cytokine secretion, expression of co-stimulatory molecules, migration to
lymph nodes, and ultimately their ability to prime naïve T cells [65].
As a model for DC maturation, CD14+monocytes from healthy
human volunteers were induced to different stages of DC maturation by
a combination of relevant cytokines and LPS from E. coli. When the S.
chinensis lignans were present in the culture medium during the ma-
turation, decrease in the secretion of IL-6, IL-10 and IL-12p40 was
control. A statistically significant (p < 0.05) decrease was achieved
with schisandrin B and schisandrin C for IL-6 (Fig. 4A), schisandrin B in
the case of IL-10 Ievels (Fig. 4B) and schisandrin and schisandrin C in
the case of IL-12p40 levels (Fig. 4C), respectively. Based on earlier
literature, glutathione depletion is linked to alter dendritic cell ma-
turation as seen by suppressed IL-6 and Il-12 secretion, yet IL-10 levels
were not affected in these studies [66,67].
For comparison, the impact of the lignans on production of IL-6, IL-
10 and IL-12p40 was also studied with human monocyte THP-1 cells.
THP-1 cells are isolated from peripheral blood of a patient suffering
from acute monocytic leukemia and it has been widely applied as a
model for innate immune system cell functions [68]. Consistent with
previous reports [68] the concentrations of secreted interleukines were
lower in THP-1 cell cultures compared to those determined from pri-
mary DC culture supernatants. Concentration of IL-6 in vehicle-treated
DCs was 30260 pg/ml and in THP-1 samples 2600 pg/ml. IL-12 con-
centrations were 18368 pg/ml and 1326 pg/ml in DCs and THP-1 cells,
respectively, indicating over 10-fold difference in these conditions.
Also, THP-1 cells did not produce IL-10 at detectable levels as did DCs
(3976 pg/ml).
Schisandrin, schisandrin B and schisandrin C lowered the IL-6 and
IL-12p40 levels in THP-1 culture supernatants at least in 50 μM con-
centration (Fig. 5A, B).
As an alternative model of monocyte activation, the THP-1 cytokine
production was also studied by stimulating the cells with an infection
by an intracellular bacterium Chlamydia pneumoniae which is known to
induce DC maturation [69]. LPS from E. coli and various other gram-
negative bacteria is recognized by monocytic cells through Toll-like
receptor 4 (TLR4), triggering signal transduction cascades involving
MyD88 and TRAM -mediated pathway and ultimately leading to up-
regulation of proinflammatory gene expression [62]. As a gram-nega-
tive bacterium, C. pneumoniae also carries LPS molecules in its outer
membrane, but the chlamydial LPS is considered to have only a minor
role in monocyte activation [70]. Instead of LPS-mediated TLR-4 acti-
vation, stimulation of innate immune system cells by C. pneumoniae is
primarily mediated via TLR-2 [71,72] but involves downstream sig-
naling cascades similar to TLR-4, including NF-B and mitogen-activated
protein kinases [73,74]. C. pneumoniae is also reported to elevate in-
tracellular ROS levels of different cell types, at least in epithelial HEp2
cell line [75] and THP-1 cells [76]. In macrophage – T Cell cultures,
reduced GSH:GSSG ratio has been reported upon C. pneumoniae infec-
tion [77]
Overall, the differential immunostimulatory nature of the isolated
LPS from E. coli and whole cells of C. pneumoniae is well illustrated by
the less intense activation of THP-1 cells by C. pneumoniae infection.
Schisandrin B and schisandrin C yet inhibits the production of IL-12
also in C. pneumoniae infected samples (Fig. 5C), demonstrating that
their mechanism of proinflammatory cytokine suppression is not lim-
ited to TLR-4-mediated triggers.
As mentioned, glutathione depletion has been reported to mediate
altered DC maturation [66,67], and thus the impact of S. chinensis lig-
nans on monocyte-derived DC maturation was further evaluated by
analyzing the appearance of DC surface proteins. The major histo-
compatibility complex II (HLA-DR) is applied by DCs for antigen pre-
senting, while CD86, in turn, is a costimulatory protein expressed on
mature antigen-presenting cells. In contrast to earlier reports on im-
munosuppressants with GSH depleting activity, none of the studied
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lignans affected the appearance of HLA-DR or CD86 on DC surface upon
maturation (Fig. 3), indicating that despite the obvious GSH decreasing
activity of schisandrin B and C, the immunomodulatory properties of
these lignans are not similar to classical immunosuppressive ther-
apeutics.
Similar to increased cytokine secretion, emergence of HLA-DR and
CD86 on DC surface is driven by TLR-mediated activation of MYD88-
dependent signaling cascades. However, in contrast to cytokine secre-
tion, the surface proteins are primarily regulated by altering their sta-
bility and subcellular localization [78,79]. Absence of HLA-DR or CD86
modulation by the lignans indicates that these compounds do not in-
teract directly with TLR4 or MYD88 and are not able to interfere with
the ubiquitin-dependent trafficking of the DC surface markers. Thus,
the molecular targets of the lignans are likely to lie in downstream
cascades and may rather involve transcriptional regulation.
Consistent with the lack of HLA-DR and CD86 modulation, schisan-
drin C did not affect the ability of DCs to activate allogenic CD4+T cells,
as no changes in T cell activation markers were observed and out of the
studied cytokines, only IL-12 levels were decreased in a statistically
significant manner. Also in this respect, the immunomodulatory profile
of schisandrin C differs from GSH-depleting immunosuppressants, vac-
cine adjuvants, or sensitizers which affect DC maturation by either
suppressing allogenic T cell activation of altering the Th1/Th2 balance
[34,66,67]. Collectively, the presented data suggests that while the im-
pact of schisandrin B and C on cellular glutathione pools is likely to
contribute to the anti-inflammatory actions of these lignans. However,
their full spectrum of biological activities is likely mediated in a cell type
and trigger-dependent fashion and warrants further studies to elucidate
the relative significance and interplay of different signaling pathways.
5. Conclusions
Previous studies on anti-inflammatory activities of schisandrin B
have indicated that this lignan triggers its biological activities by af-
fecting cellular redox status, but no data on human peripheral blood
mononuclear cells has been available in this respect. In this study we
report that schisandrin B and schisandrin C are able to decrease cellular
GSH pools in human monocytic cells. In our study, the im-
munomodulatory properties of schisandrin B and schisandrin C are
demonstrated on human monocyte-derived DCs and THP-1 cell line as
their ability to suppress IL-6, IL-10 and IL-12p40 secretion.
Despite acting as immunomodulatory agents by altering the cyto-
kine secretion, the studied lignans do not interfere with dendritic cell
maturation or T cell activating capacity as measured by surface marker
expression. Collectively, these results increase our understanding on the
potential of dibenzocyclooctadiene lignans as immunomodulatory
agents.
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